Personalized NK Cell Therapy in CBT
Public ClinicalTrials.gov record NCT02727803. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.
Study identification
- NCT ID
- NCT02727803
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Biphenotypic Leukemia
- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Acute Myeloid Leukemia With Variant MLL Translocations
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Chemotherapy-Related Leukemia
- Chronic Myelomonocytic Leukemia
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- ISS Stage II Plasma Cell Myeloma
- ISS Stage III Plasma Cell Myeloma
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts
- Myelodysplastic Syndrome With Gene Mutation
- Myelodysplastic/Myeloproliferative Neoplasm
- Previously Treated Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Refractory Acute Lymphoblastic Leukemia
- Refractory Adult Acute Lymphoblastic Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Myelodysplastic Syndrome
Interventions
- Allogeneic Natural Killer Cell Line NK-92 Biological
- Anti-Thymocyte Globulin Biological
- Busulfan Drug
- Clofarabine Drug
- Cyclophosphamide Drug
- Fludarabine Phosphate Drug
- Laboratory Biomarker Analysis Other
- Melphalan Drug
- Rituximab Biological
- Total-Body Irradiation Radiation
- Umbilical Cord Blood Transplantation Procedure
Biological · Drug · Other + 2 more
Eligibility (public fields only)
- Age range
- 15 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2016 (Actual)
- Primary completion
- May 31, 2027 (Estimated)
- Completion
- May 31, 2027 (Estimated)
- Last update posted
- Jul 30, 2026
2016 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02727803, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02727803 live on ClinicalTrials.gov.